K-PHOS #2 Rx
Generic Name and Formulations:
Potassium acid phosphate 305mg, sodium acid phosphate 700mg; equiv. to potassium 2.3mEq and sodium 5.8mEq; tabs.
Indications for K-PHOS #2:
1 tab 4 times a day with a full glass of water. If urine very alkaline, 1 tab every 2 hours; max 8 tabs daily.
Renal or adrenal insufficiency. Severe hepatic disease. Infected phosphate stones. Hyperphosphatemia. Hyperkalemia (Original).
Electrolyte restrictions. Cardiac disease. Hypertension. Edema. Monitor serum electrolytes and for GI obstruction. Discontinue if laxation persists after dosage reduction. Hypoparathyroidism. Osteomalacia. Pancreatitis. Dehydration. Toxemia of pregnancy. Pregnancy (Cat.C). Nursing mothers.
Antagonized by antacids. Hyperkalemia with ACE inhibitors, triamterene, spironolactone, amiloride, potassium supplements. Toxicity with digitalis. Hypernatremia with methyldopa, guanethidine, other antihypertensives, corticotropins, mineralocorticoids.
Small bowel lesions, laxation, headache, dizziness, hyperacidity, nausea, weakness, confusion, paresthesias, seizures, arrhythmias, shortness of breath, edema.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|